Tumor genome analysis includes germline genome: Are we ready for surprises?

65Citations
Citations of this article
80Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We sought to describe the spectrum of potential and confirmed germline genomic events incidentally identified during routine medium-throughput somatic tumor DNA sequencing, and to provide a framework for pre- and post-test consent and counseling for patients and families. Targeted tumor-only next-generation sequencing (NGS) had been used to evaluate for possible druggable genomic events obtained from consecutive new patients with metastatic gastroesophageal, hepatobiliary or colorectal cancer seen at the University of Chicago. A panel of medical oncologists, cancer geneticists and genetic counselors retrospectively grouped these patients (N = 111) based on probability of possessing a potentially inherited mutation in a cancer susceptibility gene, both prior to and after incorporating tumor-only NGS results. High-risk patients (determined from NGS results) were contacted and counseled in person by a genetic counselor (N = 21). When possible and indicated, germline genetic testing was offered. Of 8 evaluable high-risk patients, 7 underwent germline testing. Three (37.5%) had confirmed actionable germline mutations (all in the BRCA2 gene). NGS offers promise, but poses significant challenges for oncologists who are ill prepared to handle incidental findings that have clinical implications for at risk family members. In this relatively small cohort of patients undergoing tumor genomic testing for gastrointestinal malignancies, we incidentally identified 3 BRCA2 mutations carriers. This report underscores the need for oncologists to develop a framework for pre- and post-test communication of risks to patients undergoing routine tumor-only sequencing.

References Powered by Scopus

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

796Citations
N/AReaders
Get full text

Hereditary diffuse gastric cancer: Updated consensus guidelines for clinical management and directions for future research

476Citations
N/AReaders
Get full text

Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center Initiative

443Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Review of clinical next-generation sequencing

271Citations
N/AReaders
Get full text

Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline

230Citations
N/AReaders
Get full text

Precision medicine at Memorial Sloan Kettering Cancer Center: Clinical next-generation sequencing enabling next-generation targeted therapy trials

127Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Catenacci, D. V. T., Amico, A. L., Nielsen, S. M., Geynisman, D. M., Rambo, B., Carey, G. B., … Olopade, O. I. (2015). Tumor genome analysis includes germline genome: Are we ready for surprises? International Journal of Cancer, 136(7), 1559–1567. https://doi.org/10.1002/ijc.29128

Readers over time

‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘2405101520

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 32

60%

Researcher 13

25%

Professor / Associate Prof. 5

9%

Lecturer / Post doc 3

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 29

51%

Biochemistry, Genetics and Molecular Bi... 14

25%

Agricultural and Biological Sciences 10

18%

Nursing and Health Professions 4

7%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 8

Save time finding and organizing research with Mendeley

Sign up for free
0